- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
PDE5 inhibitors do not reduce risk of Alzheimer's disease and other dementias: DREAM study
Researchers have found in a new research that treatment with PDE5 inhibitors was not associated with reduced risk for Alzheimer's disease and dementia. Therefore phosphodiesterase-5 inhibitors can't be repurposed for Alzheimer's disease and related dementia.
The study was published in the journal Brain Communications.
Alzheimer's disease is the most common progressive disease of the brain causing memory loss and the ability to carry out activities of daily living. Based on the hypothesis that phosphodiesterase-5 inhibitors like sildenafil and tadalafil, may be associated with decreased incidence of Alzheimer's disease and related dementia, researchers carried out a study to find the incidence of Alzheimer's disease and related dementia among patients with pulmonary hypertension after phosphodiesterase-5 inhibitor initiation versus endothelin receptor antagonist initiation.
A patient-level cohort study using the data collected from Medicare claims and cell culture-based phenotypic assays was done among patients with pulmonary hypertension after controlling for 76 confounding variables through propensity-score matching. Four different analytic approaches were designed to address specific types of biases including informative censoring, reverse causality, and outcome misclassification.
Findings:
- Reduced risk of Alzheimer's disease and related dementia was not found after phosphodiesterase-5 inhibitors with a hazard ratio of 0.99, 1.00, 0.67, and 1.15.
- Sildenafil was not found to ameliorate the molecular abnormalities relevant to Alzheimer's disease in most cell culture-based phenotypic assays.
- No difference in the risk of Alzheimer's disease-related dementia was found between PDE5 inhibitors and endothelin receptor antagonists.
Thus, the study did not find any evidence to support the hypothesis that phosphodiesterase-5 inhibitors are promising repurposing candidates for Alzheimer's disease and related dementia.
For further reading, click here: https://doi.org/10.1093/braincomms/fcac247
Rishi J Desai, Mufaddal Mahesri, Su Been Lee, Vijay R Varma, Tina Loeffler, Irene Schilcher, Tobias Gerhard, Jodi B Segal, Mary E Ritchey, Daniel B Horton, Seoyoung C Kim, Sebastian Schneeweiss, Madhav Thambisetty, No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, Brain Communications, 2022; fcac247.
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751